Are there patient populations where nivolumab's effectiveness doesn t reach a limit?

Short answer: No, there isn’t a patient population in which nivolumab’s effectiveness is unlimited. But there are groups of patients who can have very durable, long-lasting responses that look “tail-like” on survival curves, which can feel like the benefit doesn’t end for a long time in those individuals.

What the data show
- Some cancers have more durable responses with nivolumab (and other PD-1 inhibitors) than others. Common examples with notable long-term responders include:
- Melanoma
- Renal cell carcinoma (RCC)
- Non-small cell lung cancer (NSCLC)
- Head and neck squamous cell carcinoma (HNSCC)
- MSI-H/dMMR cancers (across various tumor types)
- In several indications, a subset of patients achieves long-term survival, sometimes lasting years, even if most patients have a finite period of benefit.
- Certain biomarkers are associated with better responses, but none are perfect:
- Tumor MSI-H/dMMR status tends to predict better responses to PD-1 inhibitors.
- Higher tumor mutational burden (TMB) can be associated with better responses in some contexts.
- PD-L1 expression alone is an imperfect predictor; responses occur even in PD-L1–negative tumors.
- Conversely, some tumors are less likely to respond (so-called “hot” vs. “cold” tumors): tumors with low immune infiltration, low neoantigen load, or highly immunosuppressive microenvironments may derive less benefit. Patients with poor performance status, active autoimmune disease requiring immunosuppression, or certain comorbidities may also have reduced benefit or higher risk of adverse effects.

Key takeaways
- There isn’t a population where nivolumab has no upper limit of benefit. Rather, there are populations where long-term, durable responses are more common.
- The likelihood of durable benefit is influenced by cancer type, biomarkers (MSI-H/dMMR, TMB), prior treatments, and overall health status.
- Some patients may stop therapy after a sustained complete response and remain in remission for years; this is an area where decisions are individualized and guided by oncologists.

If you have a specific cancer type or biomarker in mind, I can summarize what is known for that scenario and what outcomes look like in long-term follow-up trials. And as always, discuss with a treating oncologist to understand how these general patterns apply to an individual case.